Imlygic (talimogene laherparepvec; Amgen) is a gene-deleted oncolytic herpes simplex virus-1 (HSV-1) that encodes human granulocyte-macrophage colony-stimulating factor (GM-CSF). Upon administration, Imlygic replicates selectively in tumor cells and generates GM-CSF. The tumor cells rupture to release GM-CSF which recruits dendritic cells and presents tumor-specific antigens. This results in activation of the immune system to kill metastatic cells while having limited effect on normal cells. Attempting to modulate the immune response is a popular strategy in melanoma, due to instances of spontaneous regression of tumors in response to immunotherapy.
LIST OF FIGURES
12 Figure 1: Imlygic in melanoma – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Imlygic for melanoma
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Imlygic for melanoma
16 Figure 4: Imlygic sales for melanoma across the US and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Imlygic drug profile
7 Table 2: Imlygic pivotal trial data in melanoma
9 Table 3: Cotellic other clinical trials in melanoma
11 Table 4: Imlygic ongoing late-phase clinical trials in melanoma
17 Table 5: Imlygic sales for melanoma across the US and five major EU markets, by country ($m), 2017–26
19 Table 6: Imlygic patient numbers for melanoma across the US and five major EU markets, by country, 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.